退伍军人事务部己酮可可碱治疗糖尿病肾病(VA PTXRx)研究:基线特征
VA PTXRx 是一项随机双盲安慰剂对照多中心试验,旨在验证己酮可可碱(PTX)能否延长2型糖尿病合并糖尿病肾病(DKD)患者至肾衰竭或死亡的时间。主要结果预计2027年公布。
要点
- PTX 400 mg每日两次对比安慰剂,主要终点为ESKD或死亡。
- 入组患者为ESKD和/或死亡极高风险人群,88%为CKD 3B或4期。
- 基线RAAS抑制剂使用率80.0%,SGLT2抑制剂52.9%。
核心结论
- 该研究将确定PTX能否成为高危DKD患者的治疗选择,结果预计2027年公布。
主要发现
- 基线平均年龄72.3岁(SD 7.7),97%为男性,平均eGFR 33.3 mL/min/1.73 m2(SD 9.4),中位UACR 401 mg/g(IQR 122-1076)。
- 基线RAAS抑制剂使用率80.0%,SGLT2抑制剂52.9%,GLP-1受体激动剂33.2%,finerenone 3.0%。
- 88%的参与者为CKD 3B或4期(eGFR < 45 mL/min/1.73m2)。
关键数值与推荐
- 研究为事件驱动,需646个主要事件(ESKD(慢性透析或移植)或死亡)以达到80%把握度检测PTX相对风险降低19%。
- 参与者按1:1随机分配至PTX 400 mg每日两次或匹配安慰剂,采用随机排列区组,按站点、RAAS抑制剂使用和CKD分期分层。
临床怎么用
- 该试验针对ESKD和/或死亡极高风险的2型糖尿病合并DKD人群,评估在常规治疗基础上加用PTX的疗效。
- 若PTX被证明有效,因其为仿制药且在许多卫生系统中价格低廉,可促进可及性。
局限性
- 97%的参与者为男性,可能限制结果外推至女性人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Experimental and clinical data suggest that the non-specific phosphodiesterase inhibitor pentoxifylline (PTX) reduces proteinuria and may delay the progression of diabetic kidney disease (DKD). However, no large-scale randomized clinical trial has determined whether PTX can reduce end-stage kidney disease (ESKD) and mortality in DKD. DESIGN: VA PTXRx is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial designed to test the hypothesis that PTX, when added to usual care, prolongs the time to kidney failure or death in type 2 diabetic (T2D) participants with DKD compared to usual care plus placebo. Enrolled participants at very high risk for ESKD and/or death were randomized in a 1:1 ratio to either PTX 400 mg twice daily or matching placebo using randomly permuted blocks with stratification for site, renin-angiotensin-aldosterone (RAAS) inhibitor use, and chronic kidney disease (CKD) stage. The study is event-driven, requiring 646 primary events (ESKD (chronic dialysis or transplantation) or death) to achieve 80% power to detect a relative risk reduction of 19% with PTX. BASELINE RESULTS: Between December 2019 and November 2025, 2376 participants at 34 VA sites in the USA were randomized. The mean age at randomization was 72.3 years (SD 7.7), with 97% being male. The mean baseline eGFR was 33.3 mL/min/1.73 m2 (SD 9.4). The median urinary albumin to creatinine ratio (UACR) was 401 mg/g (IQR 122-1076). At baseline, the usage of RAAS inhibitors was 80.0%, sodium-glucose transporter-2 (SGLT2) inhibitors 52.9%, glucagon-like peptide-1 (GLP-1) receptor agonists 33.2%, and finerenone 3.0%. The majority (88%) of participants had stage 3B or 4 CKD (eGFR < 45 mL/min/1.73m2). CONCLUSIONS: The results, anticipated in 2027, are expected to determine whether PTX is a treatment option for patients with high-risk DKD. Because PTX is a generic medication, it is inexpensive in many health systems, which would facilitate access if it proves effective. Trial Registration: This study is registered with clinicaltrials.gov (Identifier: NCT03625648).
引用
- Leehey DJ, Agarwal R, Xing B, et al. The Veterans Affairs Pentoxifylline in Diabetic Kidney Disease (VA PTXRx) Study: Baseline Characteristics. Nephrol Dial Transplant. 2026. PMID: 42911768. doi:10.1093/ndt/gfag245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。